“Pancreatic cancer stem cells could be “suffocated” by an anti-diabetic drug” – Queen Mary University of London
Review by Daniel Croagh MBBS PhD FRACS
“Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers” –
Hans Vasen, Isaura Ibrahim, Carmen Guillen Ponce, Emily P. Slater, Elvira Matthai, Alfredo Carrato, Julie Earl, Kristin Robbers, Anneke M. van Mil, Thomas Potjer, Bert A. Bonsing, Wouter H. de Vos tot Nederveen Cappel, Wilma Bergman, Martin Wasser, Hans Morreau, G¨unter Kl¨oppel, Christoph Schicker, Martin Steinkamp, Jens Figiel, Irene Esposito, Evelina Mocci, Enrique Vazquez-Sequeiros, Alfonso Sanjuanbenito, Maria Muñoz-Beltran, Jos´e Montans, Peter Langer, Volker Fendrich, and Detlef K. Bartsch.
Review by Mehrdad Nikfarjam, MD, PhD, FRACS
“Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer” –
Angus G Dalgleish*,1, Justin Stebbing 2, Douglas JA Adamson 3, Seema Safia Arif 4, Paolo Bidoli 5, David Chang 6, Sue Cheeseman 7, Robert Diaz-Beveridge 8, Carlos Fernandez-Martos 9, Rob Glynne-Jones 10, Cristina Granetto 11, Bartomeu Massuti 12, Karen McAdam 13, Raymond McDermott 14, Andre´s J Mun˜oz Martı´n 15, Demetris Papamichael 16, Roberto Pazo-Cid 17, Jose M Vieitez 18, Alberto Zaniboni 19, Kevin J Carroll 20, Shama Wagle 20, Andrew Gaya 21 and Satvinder S Mudan 22
(1)Cancer Vaccine Institute, St George’s University of London, London, UK; (2) Department of Oncology, Imperial College, Hammersmith Hospital, London, UK; (3) Department of Oncology, Ninewells Hospital, Dundee, UK; (4) Velindre Cancer Centre, Cardiff, UK; (5) Department of Oncology, Azienda Ospedaliera San Gerardo, Monza, Italy; (6) Department of General Surgery, Royal Blackburn Hospital, Blackburn, UK; (7) Department of Oncology, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK; (8) Me´dico Adjunto de Oncologı´a Me´dica, Hospital La Fe de Valencia, Valencia, Spain; (9) Instituto Valenciano de Oncologia, Valencia, Spain; (10) Mount Vernon Cancer Centre, Northwood, UK; (11) Medical Oncology, Azienda Ospedaliera Santa Croce e Carle, Cuneo, Italy; (12) Ensayos Clı´nicos Oncologı´a, Hospital General Universitario de Alicante, Alicante, Spain; (13) Oncology Department, Peterborough and Stamford Hospitals NHS Trust, Peterborough, UK; (14) Medical Oncology, St Vincent’s University Hospital and The Adelaide and Meath Hospital, Dublin, Republic of Ireland; (15) Gastrointestinal Cancer Unit, Hospital General Universitario Gregorio Maran˜ o´n, Madrid, Spain; (16) Department of Medical Oncology, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; (17) Servicio de Oncologı´a Me´dica, Hospital Miguel Servet, Zaragoza, Spain; (18) Area and Neuroendocrine Tumors Gastrointestinal Medical Oncology, Hospital Central de Asturias, Asturias, Spain; (19) Oncology Department, Fondazione Poliambulanza, Brescia, Italy; (20) TranScrip Partners LLP, Reading, UK; (21) Clinical Oncology, Guy’s & St Thomas’ Hospitals NHS Trust, London, UK and (22) St George’s University of London, Imperial College, London and The Royal Marsden Hospital, London, UK.